Imatinib - Inhibikase Therapeutics

Drug Profile

Imatinib - Inhibikase Therapeutics

Alternative Names: IkI 001; IkI-001Pro; IkT-001; IKT-001Pro PML; IKT-001Pro PVAN

Latest Information Update: 20 Aug 2015

Price : $50

At a glance

  • Originator Inhibikase Therapeutics
  • Class Antineoplastics; Antivirals; Benzamides; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive multifocal leukoencephalopathy
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Human polyomavirus infections; Progressive multifocal leukoencephalopathy

Most Recent Events

  • 13 Aug 2015 Inhibikase Therapeutics plans an observational clinical trial for Progressive multifocal leukoencephalopathy in USA
  • 21 May 2014 Imatinib - Inhibikase Therapeutics receives Orphan Drug status for Progressive multifocal leukoencephalopathy in USA
  • 16 Aug 2011 US FDA grants clearance for a phase II trial of IkT 001 in Polyomavirus infections in patients with Multiple sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top